InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.00%
)
US TECH 100
19,204.80
(
-0.05%
)
Dow Jones
39,127.80
(
0.00%
)
Brent Oil
85.21
(
0.87%
)
Bitcoin
61,372.12
(
0.89%
)
Post# of 252393
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119931
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 2319

Tuesday, 06/22/2004 3:02:26 AM

Tuesday, June 22, 2004 3:02:26 AM

Post# of 252393
Interview with Cortex's Roger Stoll,
in the Wall Street Transcript:

http://www.cortexpharm.com/pdfs/2-InterviewCOR2004.pdf

This interview, from May, 2004, contains a frank discussion of what went wrong with COR’s initial Ampakine compound, CX-516, and why the follow-on molecule, CX-717, should work a heck of a lot better. A pretty good overview of this promising --and exceptionally cheap-- company in the CNS arena.

It’s instructive to compare this TWST interview with one from last summer (#msg-3202870) to see just what has changed in the ensuing ten months.

[Thanks to ‘apoolfool’ on the Yahoo board.]

P.S. COR has a 30-minute webcast today (Tuesday):
http://biz.yahoo.com/cc/3/43473.html



“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up